Xencor, Inc.

Five Prime Therapeutics, Inc.

Exelixis, Inc.

Bristol-myers Squibb Compnay

Exelixis Pharmaceuticals, Inc.

Stephen Kohl Doberstein

John R Desjarlais

Gregory Alan Lazar

Sher Bahadur Karki

Omid Vafa

Robert J Hayes

Wei Dang

Arthur J Chirino

Lewis T Williams

Kevin Hestir

Ernestine A Lee

Elizabeth Bosch

Ge Wu

John Rudolph Desjarlais

Hongbing Zhang

Diane Hollenbaugh

Justin Wong

Minmin Qin

Ali Sadra

Shannon Marshall

Haishan Lin

Cindy Leo

Andrew Roy Buchman

Aileen Zhou

Justin G P Wong

Sheila Akiko Homburger

Dirk Behrens

Kimberly Carr Ferguson

Robert Forgan Halenbeck

Min Mei Huang

Thomas Linnemann

Chandra S Ramanathan

Michael R Costa

David Andrew Ruddy

Bindu Priya Reddy

Darren Platt

Terry Stouch

Mark Cockett

Nicholas J Lodge

Yan Wang

Lisa Moore

Rachel M Kindt

Jenny Kopczynski

Sarah L Elson

Linda Nolan Keyes

Loriane Masuoka

Kevin Fitzgerald

Justin G Wong

The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.

Optimized Fc variants and methods for their generation

Optimized FC variants and methods for their generation

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Methods of treating disease with FGFR1 fusion proteins

FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC

Optimized fc variants and methods for their generation

Polynucleotides encoding FGFR1-IIIc ECD fusion proteins

Disclosed is a newly identified secreted molecule, identified herein as 'monocyte, granulocyte, and dendritic cell colony stimulating factor' (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

Compositions and methods of use for MGD-CSF in disease treatment

Pharmaceutical polypeptide compositions promote the survival of cardiac cells, recruit cardiac cells to the cardiac area, stimulate the differentiation of cardiac cells, stimulate the proliferation of cardiac cells, and promote the activity of cardiac cells, thereby treating cardiac conditions. Methods of providing these compositions to the cardiac area include catheterization and direct injection. In preferred embodiments, the compositions comprise one of more of the following growth factors: EGF, bFGF, cardiotrophin-1, thrombin, PDGF-BB, amphiregulin, epiregulin, HB-EGF, TGFalpha, betacellulin, heregulin alpha, NRG-1-beta1-HRG-beta1, FGF 9.

Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions

Growing community of inventors

San Francisco, CA, United States of America

Stephen Kohl Doberstein